TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Smith & Nephew Snats ( (SNN) ) just unveiled an update.
On December 8, 2025, Smith+Nephew announced its new RISE strategy and financial targets for 2028 at its Capital Markets Day in London. The strategy aims to elevate financial and operational performance, focusing on reaching more patients, innovating product offerings, scaling operations, and executing efficiently. The company updated its 2025 full-year guidance, expecting a trading profit margin of at least 19.5% and free cash flow around $800 million. Smith+Nephew also plans to rationalize its product portfolio, estimating a $200 million non-cash inventory provision in 2025 to simplify offerings and improve capital efficiency. The RISE strategy is expected to deliver significant shareholder value and solidify Smith+Nephew’s leadership in healthcare innovation.
The most recent analyst rating on (SNN) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Neutral.
Smith & Nephew Snats’ strong financial performance and positive earnings call are the main drivers of its stock score. However, bearish technical indicators and a high P/E ratio temper the overall outlook. The company’s strategic initiatives, such as the share buyback, reflect confidence in its financial health, but challenges in emerging markets and tariff impacts pose risks.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith+Nephew is a global medical technology company specializing in products for sports medicine, advanced wound management, ear, nose, and throat (ENT), and orthopaedics. The company focuses on innovation to enhance patient care and aims to drive growth and efficiency through strategic investments and portfolio management.
Average Trading Volume: 612,502
Technical Sentiment Signal: Buy
Current Market Cap: $14.32B
See more insights into SNN stock on TipRanks’ Stock Analysis page.